Lowder J N, Meeker T C, Levy R
Cancer Surv. 1985;4(2):359-75.
Monoclonal antibodies which bind to tumour cell surface antigens have produced regressions of malignancies in an increasing number of clinical trials. The largest experience to date is in the treatment of refractory B and T lymphoid tumours using a variety of intravenously administered mouse monoclonal antibodies. Treatment with antibodies against common differentiation antigens or very specific anti-idiotype antibodies has been effective in both cases. Toxicity has been acceptably low. A number of problems which limit the application and efficacy of monoclonal antibody therapy of lymphoid malignancy have been identified. Most prominent among these are tumour heterogeneity, which allows non-antibody binding subpopulations of the tumour to escape therapy, and the patient's immunological response to the monoclonal antibody-tumour cell complex. As more experience is accumulated, solutions to these problems will be found.
在越来越多的临床试验中，与肿瘤细胞表面抗原结合的单克隆抗体已使恶性肿瘤出现消退。迄今为止，最大规模的经验是使用多种静脉注射的小鼠单克隆抗体治疗难治性B和T淋巴细胞肿瘤。在这两种情况下，使用针对常见分化抗原的抗体或非常特异的抗独特型抗体进行治疗均有效。毒性一直低到可以接受的程度。已经发现了一些限制单克隆抗体治疗淋巴恶性肿瘤的应用和疗效的问题。其中最突出的是肿瘤异质性，它使肿瘤中不与抗体结合的亚群逃避治疗，以及患者对单克隆抗体 - 肿瘤细胞复合物的免疫反应。随着积累的经验越来越多，将找到解决这些问题的办法。
